Betrixaban - Portola Pharmaceuticals

Drug Profile

Betrixaban - Portola Pharmaceuticals

Alternative Names: Bevyxxa; Dexxience; MK-4448; MLN-1021; PRT 021; PRT 054021

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Portola Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Benzamides; Imines; Pyridines; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Venous thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 25 Aug 2018 Efficacy and safety data from the phase III APEX trial in Venous thromboembolism presented at the Annual Congress of the European Society of Cardiology (ESC Congress - 2018)
  • 30 Jul 2018 The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) maintains negative opinion on the Marketing Authorisation Application (MAA) of betrixaban for Venous thromboembolism
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top